IONS News and Press, Ionis Pharmaceuticals Inc. From 02/25/26

2026-02-25 14:15:04 ET Needham analyst issues BUY recommendation for IONS on February 25, 2026 07:08PM ET. The previous analyst recommendation was Buy. IONS was trading at $81.16 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ana...

2026-02-25 12:58:32 ET More on Ionis Pharmaceuticals Ionis Pharmaceuticals, Inc. (IONS) Q4 2025 Earnings Call Transcript Ionis Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenu...

2026-02-25 12:57:52 ET Ionis Pharmaceuticals, Inc. (IONS) Q4 2025 Earnings Call February 25, 2026 8:30 AM EST... Read the full article on Seeking Alpha For further details see: Ionis Pharmaceuticals, Inc. (IONS) Q4 2025 Earnings Call Transcript

2026-02-25 07:01:39 ET More on Ionis Pharmaceuticals Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue Growth Ionis Pharmaceuticals, Inc. (IONS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Ionis Pharmaceuticals, Inc. (I...

- TRYNGOLZA ® generated $108 million in net product sales in 2025, the first year of launch – - Olezarsen sHTG launch preparations on track, sNDA submitted - - Exceeded 2025 financial guidance, 2026 guidance reflects commitment to independently deliver a steady cad...

HCI Group Inc. (HCI) is expected to report $4.87 for Q4 2025 XPEL Inc. (XPEL) is expected to report $0.43 for Q4 2025 Oversea-Chinese Banking Corporation Limited ADR (OVCHY) is expected to report $0.56 for Q4 2025 UMH Properties Inc. (UMH) is expected to report $0.24 for Q4 2025 I...

2026-02-24 10:10:16 ET More on Ionis Pharmaceuticals Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue Growth Ionis Pharmaceuticals, Inc. (IONS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Ionis Pharmaceuticals, Inc. (I...

2026-02-23 07:26:20 ET PTC Therapeutics ( PTCT ) is entering a new phase of growth as newer products begin to replace older revenue sources. I believe the recent launch of Sephience, an oral therapy approved for the treatment of phenylketonuria (PKU), a rare genetic disorder that pr...

2026-02-22 08:07:08 ET The last week of February brings another packed stretch of earnings, with a mix of megacap technology leaders, consumer bellwethers, energy producers, financial firms, and high-growth disruptors set to report.... Read the full article on Seeking Alpha For ...

Webcast scheduled for Wednesday, February 25 at 8:30 a.m. Eastern Time Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced a change in the start time for its fourth quarter and full year 2025 financial results webcast. The live webcast, previously scheduled for 11:30 a.m. E...